venBio Global Strategic Fund III L.P. 13D and 13G filings for Elevation Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-08-08 9:05 pm Sale | 2024-08-08 | 13D | Elevation Oncology, Inc. ELEV | venBio Global Strategic Fund III L.P. | 2,031,920 3.400% | -505,851 (-19.93%) | Filing |
| 2023-06-15 4:30 pm Purchase | 2023-06-13 | 13D | Elevation Oncology, Inc. ELEV | venBio Global Strategic Fund III L.P. | 2,537,771 6.100% | 671,432 (+35.98%) | Filing |
| 2022-09-26 4:21 pm Unchanged | 2021-06-29 | 13D | Elevation Oncology, Inc. ELEV | venBio Global Strategic Fund III L.P. | 1,866,339 8.000% | 0 (Unchanged) | Filing |
| 2022-05-27 5:26 pm Sale | 2022-05-25 | 13D | Elevation Oncology, Inc. ELEV | venBio Global Strategic Fund III L.P. | 1,866,339 8.030% | -741,828 (-28.44%) | Filing |
| 2021-07-09 4:01 pm Purchase | 2021-06-29 | 13D | Elevation Oncology, Inc. ELEV | venBio Global Strategic Fund III L.P. | 2,608,167 11.430% | 2,608,167 (New Position) | Filing |